Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Patent
1994-05-13
1998-07-14
Bawa, Raj
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
424450, 424 851, 424 852, A61K 912
Patent
active
057800120
ABSTRACT:
A method for administering to a patient having at least one affliction of infections, immunodeficiency syndromes, inflammatory diseases, autoimmune diseases, foreign body transplants, or requiring immuno-regulation of tumor diseases, which is present in the lungs. The method administers a non-systemic inhalation of an aerosol composition to the lungs effective to reduce the affliction. The aerosol composition is a solution of a cytokine and a pharmaceutically acceptable aqueous carrier solution. The aerosol composition is uniformly administered to the patient over a course of treatment of several months.
REFERENCES:
patent: 4863727 (1989-09-01), Zimmerman et al.
patent: 5011678 (1991-04-01), Wang et al.
patent: 5037644 (1991-08-01), Shaked et al.
patent: 5049389 (1991-09-01), Radhakrishnan
patent: 5162507 (1992-11-01), Wolfe et al.
Lotze, M.T., et al, "Clinical Effects and Toxicity of Interleukin-2 in Patients With Cancer" Cancer 58: 2764, 1986.
Thompson, J.A., et al, "Recombinant Interleukin-2 Toxicity, Pharmacokinetics, and Immunomodulatory Effects in a Phase 1 Trial" Cancer Res. 47:4202, 1987.
West, W.H., et al, "Constant-Infusion Recombinant-Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer" N.Engl.J.Med.: 898, 1987.
Lotze, M.T., et al, "High-Dose Recombinant Interleukin-2 in The Treatment of Patients with Disseminated Cancer" J.A.M.A. 256:3117, 1986.
Rosenberg, S.A., et al, "A Progress Report on the Treatment of 157 Patients with Advanced Cancer using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone" New Engl.J.Med. 316: 898, 1987.
Kucharz, E.J., et al. "Serum Inhibitors of Interleukin-2" Life Sci. 42: 1485, 1988.
Forni G., et al. "Tumor Immunotherapy by Local Injection of Interleukin-2 and Non-Reactive Lymphocytes", Prog. Exp.Tumor Res. 32: 187, 1988.
Gramatzki, M. et al, "Intralymphatic Interleukin-2 Treatment in Patients with Acquired Immunodeficiency Syndrome: Preliminary Experience in Three Case" Immunobiol.172:438,1986.
Bubenik, J. "Local immunotherapy of cancer with interleukin-2", Immunol. Let. 21: 267, 1989.
Lotze, M.T., et al. "Intraperitoneal Administration of Interleukin-2 in Patients with Cancer" Arch. Surg. 121: 1373, 1986.
Yasumoto, K., et al. "Induction of Lymphokine-activated Killer Cells by Intrapleural Instillations of Recombinant Interleukin-2 in Patients with Malignant Pleurisy Due to Lung Cancer" Cancer Res. 47: 2184, 1987.
Rosenberg, S.A. "Immunotherapy of Cancer by Systemic Admin. of Lymphoid Cells Plus Interleukin-2", J. Biol. Resp Mod 3: 501, 1984.
Mittelman, A., et al, "Treatment of Patients with Advanced Cancer Using Multiple Long-Term Cultured Lymphokine-Activated Killer (LAK) Cell Infusions and Recombinant Human Interleukin-2", J.Biol.Resp.Mod. 8: 468, 1989.
Rosenberg, S.A. "Lymphokine-Activated Killer Cells: A New Approach to Immunotherapy of Cancer",J.N.C.I. 75: 595, 1985.
Paciucci, P.A., et al, "Recombinant Interleukin-2 by Continuous Infusion and Adoptive Transfer of Recombinant Interleukin-2-Activated Cells in Patients with Advanced Cancer", J. Clin. Oncol. 7: 869, 1989.
Grimm, E.A., et al, "Lymphokine-Activated Killer Cell Phenomenon", J. Exp. Med. 155: 1823, 1982.
Rosenberg, S.A. "Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 To Patients with Metastatic Cancer", N.Engl.J.Med. 313: 1485, 1985.
Belldegrun, A., "Lymphokines and activated cells in experimental and clinical immunotherapy" In: Immunotherapy of Urological Tumors (ed.deKernion JB), Churchill Livingston 1990.
Oliver, R.T.D. "The Clinical Potential of Interleulin-2" Br. J. Cancer 58,405-409, 1988.
Huland, Edith, et al, "Inhaled Interleukin-2 in Combination with low-dose systemic interleukin-2 and interferon-a in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity on mainly local treatment" J. Cancer Res. Clin. Oncol 120:221-228, 1994.
Van Zandwijk, et al, Aerosol Application Of Interferon-Alpha In The Treatment Of Bronchioalveolar Carcinoma, European Journal Of Cancer, vol. 26, No. 6, pp. 738-740, 1990.
Kinnula, V., et al., Effect Of Inhaled Natural Interferon-Alpha On Diffuse Bronchioalveolar Carcinoma, European Journal Of Cancer, vol. 26, No. 6, pp. 740-741, 1990.
Kinnula, V., et al, Pharmacokinetics And Toxicity Of Inhaled Human Interferon-Alpha In Patients With Lung Cancer, Journal Of Interferon Research, 9: pp. 419-423, 1989.
Flexman, JP, et al; In Vivo Boosting Of Lung Natural Killer And Lymphokine-Activated Killer Cell Activity By Interleukin-2: Comparison Of Systemic Intrapleural And Inhalation Routes Clin.Exp.Immunol, 82(1), pp. 151-156, 1990.
Huland Edith
Huland Hartwig
LandOfFree
Method for reducing lung afflictions by inhalation of cytokine s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for reducing lung afflictions by inhalation of cytokine s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for reducing lung afflictions by inhalation of cytokine s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1879160